Pancreatic Cancer: How deadly is the future?
Pancreatic cancer is set to become the second leading cause of cancer-related deaths in the US in 2020 after lung cancer, despite accounting for only 3% of new cancer diagnoses. Patients with advanced pancreatic cancer have a median survival of approximately 2.8-5.7 months, even in light of recent therapeutic innovations and elucidation of fundamental biological mechanisms of the disease. In the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) approximately two-thirds of patients are diagnosed with unresectable Stage III or Stage IV metastatic disease, and a significant proportion of resectable Stage III disease (85%) progresses to metastatic pancreatic cancer.
Since 2013, the FDA and European Medicines Agency (EMA) have approved Celgenes Abraxane (nab-paclitaxel), followed by Ipsens Onivyde (irinotecan liposome injection). On the one hand, the addition of these novel therapeutic agents to existing regimens provides renewed hope to improve the treatment outcomes of patients with pancreatic cancer. On the other hand though, the pancreatic cancer field is littered with numerous clinical trial failures and successful readouts are notably sparse. In 2016, five Phase III agents were discontinued from development, exacerbating the aridity of a barren pancreatic cancer pipeline. However, there are general grounds for optimism as the therapeutic landscape is being transformed by novel frontline combination regimens as well as concrete options beyond this, for cases of disease progression. The integration of second-line therapy into the treatment algorithm of advanced pancreatic adenocarcinoma requires refinement in order to become an essential strategic component against the disease.
Key Questions Answered
- What are the key drivers behind the uptake and sustained dominance of Abraxane in the pancreatic cancer space, and what are the prevailing trends regarding its use over the forecast period?
- The pancreatic cancer market is characterized by a number of unmet needs. What are the main unmet needs in this market? Will the pipeline drugs under development fulfil these unmet needs?
- What impact will label expansion of advanced treatments into the lucrative adjuvant setting and targeted therapies into the front-line setting have?
VIEW FULL REPORT
Scope
- Overview of pancreatic cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized pancreatic cancer therapeutics market revenue, cost of therapy per patient, treatment usage patterns in five patient segments, and forecasts from 2016 to 2026.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the pancreatic cancer therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for pancreatic cancer. The most promising candidates in Phase III development are profiled.
- Analysis of the current and future market competition in the global pancreatic cancer market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global pancreatic cancer market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global pancreatic cancer market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships
Since 2013, the FDA and European Medicines Agency (EMA) have approved Celgenes Abraxane (nab-paclitaxel), followed by Ipsens Onivyde (irinotecan liposome injection). On the one hand, the addition of these novel therapeutic agents to existing regimens provides renewed hope to improve the treatment outcomes of patients with pancreatic cancer. On the other hand though, the pancreatic cancer field is littered with numerous clinical trial failures and successful readouts are notably sparse. In 2016, five Phase III agents were discontinued from development, exacerbating the aridity of a barren pancreatic cancer pipeline. However, there are general grounds for optimism as the therapeutic landscape is being transformed by novel frontline combination regimens as well as concrete options beyond this, for cases of disease progression. The integration of second-line therapy into the treatment algorithm of advanced pancreatic adenocarcinoma requires refinement in order to become an essential strategic component against the disease.
Key Questions Answered
- What are the key drivers behind the uptake and sustained dominance of Abraxane in the pancreatic cancer space, and what are the prevailing trends regarding its use over the forecast period?
- The pancreatic cancer market is characterized by a number of unmet needs. What are the main unmet needs in this market? Will the pipeline drugs under development fulfil these unmet needs?
- What impact will label expansion of advanced treatments into the lucrative adjuvant setting and targeted therapies into the front-line setting have?
VIEW FULL REPORT
Scope
- Overview of pancreatic cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized pancreatic cancer therapeutics market revenue, cost of therapy per patient, treatment usage patterns in five patient segments, and forecasts from 2016 to 2026.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the pancreatic cancer therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for pancreatic cancer. The most promising candidates in Phase III development are profiled.
- Analysis of the current and future market competition in the global pancreatic cancer market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global pancreatic cancer market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global pancreatic cancer market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships
CONTACT US -
JSB Market Research Pvt Ltd.
Contact Us : +91 7710006748
Website: www.jsbmarketresearch.com
Email us: gauri@jsbmarketresearch.com
Comments
Post a Comment